Slide 1: MaxCyte Partnership Portfolio
MaxCyte Partnership Portfolio August 12, 2026 are trademarks of MaxCyte, Inc. in the U.S.A. © 2026 MaxCyte, Inc. All Rights Reserved
Slide 2: MaxCyte has an Active Portfolio of SPLs
MaxCyte has an Active Portfolio of SPLs 29 SPL Partners1 7 SPL partners in preclinical 11 SPL partners in clinical 11 SPL partners in research3 17 preclinical programs 12 clinical programs2 cGMP Compatible Platform Beam Therapeutics FDA Master File and Technical Files Experienced FAS and Sana ` Biot
Slide 3: SPL Portfolio: 14 Active Clinical Trials
SPL Portfolio: 14 Active Clinical Trials Partner Program Phase Cell Approach Cell Type Disease Area Vertex Pharmaceuticals CASGEVY Commercial Autologous HSCs Beta-thalassemia Vertex Pharmaceuticals CASGEVY Commercial Autologous HSCs Sickle cell disease Wugen WU-CART-007 Pivotal Allogeneic T-Cells T
Slide 4: Expanding Opportunity: Growth in Therapeutic Areas and Clinical SPL Programs
Expanding Opportunity: Growth in Therapeutic Areas and Clinical SPL Programs SPL Trials Across SPL Programs (Clinical & Commercial) Multiple Therapeutic Areas 20 Therapeutic Clinical/ Pre-Clinical 18 Area Commercial 16 Genetic Disease 5 1 14 12 Blood Cancer 4 0 10 Solid Tumor 3 14 8 6 Autoimmune Dis
Slide 5: MaxCyte Supports the Future of Cell & Gene Therapies
MaxCyte Supports the Future of Cell & Gene Therapies WAVE 1 WAVE 2 WAVE 3 WAVE 4 1 Approved Product 5 Product Candidates 7 Product Candidates 17 Product Candidates Vertex/ CRISPR Launch Potential: Launch Potential: Launch Potential: CASGEVY® 2027 – 2028 2028 + 2032 + Approved 2023 5 products set to
Slide 6: Second Wave Set to Enter Pivotal Studies in Next 6 to 18 Months
Second Wave Set to Enter Pivotal Studies in Next 6 to 18 Months SPL Clinical Programs Phase Cell Type Cell Approach Indication B-cell CTX112 1/2 T-cells Allogeneic Malignancies Hematologic WU-CART-007 Pivotal T-cells Allogeneic Malignancies Hematologic Azer-Cel 1/1b T-Cells Allogeneic Malignancies U
Slide 7: Illustrative Revenue Profile for a Successful SPL Program
Illustrative Revenue Profile for a Successful SPL Program Revenue Growth Drivers: Significant development Assumptions: First Approval in Year 7 | Approval in Three Geographic Regions milestones and high-value participation in future $1.0B Peak Sales | Peak Sales Commercial Year 7 | Royalty 1.0% comm
Slide 8: Genentech Partnership Multi-Platform Technology License Partnership
Genentech Partnership Multi-Platform Technology License Partnership An enterprise-level relationship providing Genentech access to MaxCyte's ExPERT GTx® platform and additional platform technologies across research, clinical development, and commercial manufacturing workflows Enterprise Framework Pl
Slide 9: An Expanding Partnering Model for Large Pharma
An Expanding Partnering Model for Large Pharma Enterprise partnerships complement MaxCyte's Strategic Platform License (SPL) model Strategic Platform License (SPL) Enterprise Partnership (Example: Genentech) Product-by-product Portfolio-wide Non-exclusive license to ExPERTTM platform for biotechs En
Slide 10: Thank you! Any questions?
Thank you! Any questions? ir@maxcyte.com ©2025 MaxCyte, Inc. All rights reserved. For a complete list of MaxCyte trademarks in the United States and other countries, please visit maxcyte.com/trademarks. All other trademarks are the property of their respective owners. 10 © 2026 MaxCyte, Inc. All Rig